These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 11775880)

  • 1. [Gibbs-Sampler approach for meta-analysis of multiple clinical trials using generalized linear model with random-effects].
    Wang Y; Wang Y; Li L; Wang Z; Macus F; Salim Y
    Chin Med J (Engl); 2000 Jun; 113(6):554-7. PubMed ID: 11775880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
    Reboldi G; Angeli F; Cavallini C; Gentile G; Mancia G; Verdecchia P
    J Hypertens; 2008 Jul; 26(7):1282-9. PubMed ID: 18550998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials.
    Volpe M; Tocci G; Sciarretta S; Verdecchia P; Trimarco B; Mancia G
    J Hypertens; 2009 May; 27(5):941-6. PubMed ID: 19381108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent events in meta-analysis of multiple clinical trials.
    Wang Y; Flather M; Yusuf S; Wang YH; Li LX; Wang ZC
    Zhongguo Yao Li Xue Bao; 1999 Jun; 20(6):495-9. PubMed ID: 10678139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
    Saha SA; Molnar J; Arora RR
    Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian random effects meta-analysis of trials with binary outcomes: methods for the absolute risk difference and relative risk scales.
    Warn DE; Thompson SG; Spiegelhalter DJ
    Stat Med; 2002 Jun; 21(11):1601-23. PubMed ID: 12111922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
    Sun SX; Ye X; Lee KY; Dupclay L; Plauschinat C
    Clin Ther; 2008; 30 Pt 2():2217-27. PubMed ID: 19281916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue ACE inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular function: a pooled meta-analysis of randomized placebo-controlled trials.
    Saha SA; Molnar J; Arora RR
    J Cardiovasc Pharmacol Ther; 2007 Sep; 12(3):192-204. PubMed ID: 17875946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175,634 patients.
    Costanzo P; Perrone-Filardi P; Petretta M; Marciano C; Vassallo E; Gargiulo P; Paolillo S; Petretta A; Chiariello M
    J Hypertens; 2009 Jun; 27(6):1136-51. PubMed ID: 19451836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M
    J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do angiotensin II receptor blockers increase the risk of myocardial infarction?
    Verdecchia P; Angeli F; Gattobigio R; Reboldi GP
    Eur Heart J; 2005 Nov; 26(22):2381-6. PubMed ID: 16081468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.
    Dahabreh IJ; Economopoulos K
    Clin Trials; 2008; 5(2):116-20. PubMed ID: 18375649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Role of angiotensin-converting enzyme inhibitors in the treatment of heart failure in the 21st century].
    Gibelin P
    Arch Mal Coeur Vaiss; 2002 Feb; 95 Spec 4(5 Spec 4):41-5. PubMed ID: 11933555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-regression detected associations between heterogeneous treatment effects and study-level, but not patient-level, factors.
    Schmid CH; Stark PC; Berlin JA; Landais P; Lau J
    J Clin Epidemiol; 2004 Jul; 57(7):683-97. PubMed ID: 15358396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigating trial and treatment heterogeneity in an individual patient data meta-analysis of survival data by means of the penalized maximum likelihood approach.
    Rondeau V; Michiels S; Liquet B; Pignon JP
    Stat Med; 2008 May; 27(11):1894-910. PubMed ID: 18069745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: a meta-analysis.
    Verdecchia P; Angeli F; Cavallini C; Gattobigio R; Gentile G; Staessen JA; Reboldi G
    Eur Heart J; 2009 Mar; 30(6):679-88. PubMed ID: 19168534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials.
    Tokmakova M; Solomon SD
    Curr Opin Cardiol; 2006 Jul; 21(4):268-72. PubMed ID: 16755193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation.
    Anand K; Mooss AN; Hee TT; Mohiuddin SM
    Am Heart J; 2006 Aug; 152(2):217-22. PubMed ID: 16875900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AT1 receptor blockade for the prevention of cardiovascular events after myocardial infarction.
    Azadpour M; Lamas GA
    Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):891-902. PubMed ID: 15500434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.